SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

3 marketing jobs

Summit Therapeutics logo
8 days ago

Senior Director, Regional Marketing

Summit Therapeutics

Princeton, NJ (On-site)Full time$220K/yr – $270K/yr
Summit Therapeutics logo
2 weeks ago

Director, Marketing Operations

Summit Therapeutics

Princeton, NJ (On-site)Full time$203K/yr – $253K/yr
Summit Therapeutics logo
5 weeks ago

Associate Director, HCP Promotional Marketing

Summit Therapeutics

Princeton, NJ (On-site)Full time$174K/yr – $205K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Summit Therapeutics logo

Senior Director, Regional Marketing

Summit Therapeutics

Princeton, NJ (On-site)

$220K/yr - $270K/yrIn-houseFull-timeSenior level12+ years exp.
8 days ago
Summit Therapeutics logo

Director, Marketing Operations

Summit Therapeutics

Princeton, NJ (On-site)

$203K/yr - $253K/yrIn-houseFull-timeDirector/executive
2 weeks ago
Summit Therapeutics logo

Associate Director, HCP Promotional Marketing

Summit Therapeutics

Princeton, NJ (On-site)

$174K/yr - $205K/yrIn-houseFull-timeSenior level8+ years exp.
5 weeks ago
Summit Therapeutics logo
Summit Therapeutics

Senior Director, Regional Marketing

Princeton, NJ (On-site)

$220K/yr – $270K/yrSenior Level12+ years expFull time

Posted 8 days ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the U.S. regional marketing strategy and build a high-performing team to drive commercial objectives through regional insights, customer engagement, and cross-functional leadership.

  • Lead regional strategy, KPIs, and governance
  • Develop and mentor Regional Marketing Directors and align cross-functional partners

Job Description

Responsibilities

  • Establish and lead the overall U.S. regional marketing strategy and operating model, ensuring alignment with corporate, brand, launch, and commercial objectives.
  • Establish strategic priorities, objectives, KPIs, and performance expectations for the regional marketing organization and ensure consistent execution across regions.
  • Provide strategic oversight of regional customer engagement initiatives, ensuring resources and activities are appropriately prioritized against the highest-value opportunities.
  • Serve as a senior strategic advisor to Commercial leadership on regional market opportunities, customer dynamics, competitive intelligence, and implications for brand and commercial strategy.
  • Partner with Marketing leadership to ensure regional insights meaningfully influence brand strategy, positioning, segmentation, customer engagement, and launch planning.
  • Build, recruit, hire, onboard, develop, and lead a high-performing team of Regional Marketing Directors aligned to the Company's evolving commercial and geographic needs.
  • Establish the organizational structure, roles, responsibilities, capabilities, and performance expectations necessary to support a high-performing regional marketing organization.
  • Provide ongoing leadership, coaching, mentoring, and development to Regional Marketing Directors, fostering a culture of accountability, collaboration, innovation, and customer-centricity.
  • Establish and maintain consistent regional marketing standards, operating processes, and governance across the team while allowing appropriate flexibility based on market-specific needs.
  • Establish the strategic framework for engagement with National and Regional Thought Leaders, including segmentation, prioritization, engagement planning, and cross-functional coordination.

Requirements

  • Bachelor's degree in Marketing, Business, or a related field, or an equivalent combination of education and experience; advanced degree preferred.
  • Minimum of 12+ years of progressive experience in pharmaceutical, biotechnology, or healthcare marketing, with demonstrated experience supporting commercial products and/or launches.
  • Demonstrated leadership experience building, recruiting, developing, and managing high-performing marketing teams, preferably within a pharmaceutical or biotechnology organization.
  • Demonstrated experience leading regional marketing strategy and organizational capabilities within the U.S. pharmaceutical or biopharmaceutical industry.
  • Oncology experience is required, with experience supporting the commercialization and/or launch of oncology products strongly preferred.
  • Demonstrated ability to translate national brand strategy into differentiated regional strategies and customer engagement approaches.
  • Strong understanding of the U.S. healthcare ecosystem, including payer dynamics, treatment pathways, healthcare delivery systems, and the evolving oncology marketplace.
  • Demonstrated experience engaging with National and Regional Thought Leaders, key healthcare stakeholders, and other priority customers.
  • Experience providing strategic oversight of commercial advisory boards, speaker programs, congress strategy and execution, and other customer engagement initiatives.
  • Demonstrated ability to synthesize complex customer, market, and competitive insights and translate them into actionable strategic recommendations.

Preferred

  • Advanced degree preferred.
Summit Therapeutics logo

Summit Therapeutics

Summit Mission Statement:To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate.We accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position. Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK.

Founded in 2003
Miami, Florida, USA
321 employees
www.smmttx.com

Salaries

Posted range

$220K/yr – $270K/yr

Taken straight from the job posting.

See all Summit Therapeutics salaries

Marketing Team

Median Tenure
0.7 years
Marketing Roles Posted (Last 30 Days)
3

Funding

Total Funding
$1.8B
Last Raise
$500M
Post IPO Equity, 5 months ago

Funding History

  • Oct 2025
    Post IPO Equity • $500M
  • Sep 2024
    Post IPO Equity • $235M
  • Jun 2024
    Post IPO Equity • $200M

Traffic Signals

Monthly Visitors
34.1K
Traffic Source Mix
Search
50.3%
Direct
40.7%
Referral
6.3%
Social
1.6%
Paid
1.1%

Headcount Trend

Current headcount: ~325

Recent News

Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development
Dec 11, 2025 • Yahoo Finance
Don't Buy Summit Therapeutics Until This Big Thing Happen
Dec 3, 2025 • Nasdaq
Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases
Dec 2, 2025 • Yahoo Finance
January 2026 Options Now Available For Summit Therapeutics (SMMT)
Nov 26, 2025 • Nasdaq
Summit Therapeutics Inc Reports Positive Phase III Trial Results
Nov 7, 2025 • TradingView — Track All Markets
Summit Therapeutics to Present at Upcoming Investor Conferences
Nov 4, 2025 • Business Wire
Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed?
Nov 3, 2025 • Yahoo Finance
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025
Oct 30, 2025 • Yahoo Finance
Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares
Oct 28, 2025 • Yahoo Finance
Thursday’s Insider Moves: Summit Therapeutics’ Directors Lead Buying Spree
Oct 24, 2025 • Investing.com
Summit Therapeutics: A Risky Bet in the Biotech Arena?
Oct 24, 2025 • The Motley Fool
Summit Therapeutics Raises $500 Million in Private Placement
Oct 22, 2025 • Business Wire
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab
Oct 21, 2025 • Yahoo Finance
Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ...
Oct 20, 2025 • Yahoo Finance
Summit Therapeutics Posts Wider Loss In Q3
Oct 20, 2025 • Nasdaq
What's Going On With Summit Therapeutics Stock On Monday? - Summit Therapeutics (NASDAQ:SMMT)
Oct 20, 2025 • Benzinga
Summit Therapeutics Inc. SEC 10-Q Report
Oct 20, 2025 • TradingView — Track All Markets
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
Oct 20, 2025 • Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Oct 18, 2025 • PR Newswire
Summit Therapeutics (SMMT): A Valuation Perspective After Recent 16% Share Price Climb
Oct 18, 2025 • Yahoo Finance
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
Oct 17, 2025 • Business Wire
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Oct 15, 2025 • Yahoo Finance
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Oct 15, 2025 • Business Wire
Where is Summit Therapeutics (SMMT) Headed According to Analysts?
Oct 7, 2025 • Yahoo Finance
A Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal Investigation
Oct 2, 2025 • Yahoo Finance
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025
Oct 1, 2025 • Yahoo Finance
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 24, 2025 • Business Wire
Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China
Sep 18, 2025 • Yahoo Finance
Barclays Initiates Coverage of Summit Therapeutics (SMMT) with Underweight Recommendation
Sep 17, 2025 • Nasdaq
Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
Sep 16, 2025 • GlobeNewswire
Summit Therapeutics stock gains on insider buys (SMMT:NASDAQ)
Sep 12, 2025 • Seeking Alpha
Summit Therapeutics Stock (SMMT) Opinions on HARMONi Trial Data Release | SMMT Stock News
Sep 12, 2025 • Quiver Quantitative
Duggan buys Summit Therapeutics (SMMT) shares worth $5.9m
Sep 11, 2025 • Investing.com
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
Sep 10, 2025 • GlobeNewswire
Summit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval Questions
Sep 10, 2025 • Yahoo Finance
Summit’s Stock Plunge: What Lies Ahead?
Sep 10, 2025 • StocksToTrade
Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating
Sep 10, 2025 • Insider Monkey
Is Summit Therapeutics a Buy, Sell, or Hold Now?
Sep 9, 2025 • Nasdaq
Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating
Sep 9, 2025 • Yahoo Finance
Summit Therapeutics Enters Oversold Territory (SMMT)
Sep 8, 2025 • Nasdaq
Summit's High-Profile Drug Flops And Shares Crash
Sep 8, 2025 • Investor's Business Daily
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Sep 8, 2025 • Yahoo Finance
Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend
Sep 7, 2025 • Fierce Pharma
Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster
Sep 7, 2025 • statnews.com
Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3
Sep 4, 2025 • Stocktwits
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
Sep 3, 2025 • Business Wire
H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44
Aug 30, 2025 • Yahoo Finance
Summit Therapeutics stock price target raised to $50 from $44 at H.C. Wainwright
Aug 27, 2025 • Investing.com
Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism
Aug 18, 2025 • Yahoo Finance
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call
Aug 13, 2025 • Yahoo Finance
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11, 2025 • Yahoo Finance
Summit Therapeutics Inc. SEC 10-Q Report
Aug 11, 2025 • TradingView
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Aug 11, 2025 • Business Wire
Summit Therapeutics Insiders Added US$78.0m Of Stock To Their Holdings
Aug 2, 2025 • Yahoo Finance
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings
Jul 17, 2025 • Yahoo Finance
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors (SMMT)
Jul 17, 2025 • Seeking Alpha
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
Jul 14, 2025 • Business Wire
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal
Jul 10, 2025 • Yahoo Finance
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal
Jul 10, 2025 • Insider Monkey
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal
Jul 9, 2025 • Yahoo Finance
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Jul 7, 2025 • Yahoo Finance
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Jul 6, 2025 • Yahoo Finance
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Jul 4, 2025 • Seeking Alpha
Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
Jul 3, 2025 • Reuters
Summit Is in Talks for $15 Billion Partnership With AstraZeneca
Jul 3, 2025 • Bloomberg.com
Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks
Jul 3, 2025 • Investopedia
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Jul 2, 2025 • Nasdaq
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
Jul 1, 2025 • Yahoo Finance
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Jun 30, 2025 • Yahoo Finance
Revolution Medicines and Summit Therapeutics Enter into
Jun 30, 2025 • GlobeNewswire
H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
Jun 25, 2025 • Yahoo Finance
Why Summit Therapeutics Stock Tanked Today
Jun 11, 2025 • Nasdaq
Why Summit Therapeutics Stock Tanked Today
Jun 11, 2025 • Yahoo Finance
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm
Jun 6, 2025 • GlobeNewswire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 6, 2025 • Business Wire
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
Jun 5, 2025 • Yahoo Finance
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday
Jun 4, 2025 • Yahoo Finance
Summit Therapeutics: What's This Ivonescimab Rollercoaster
Jun 3, 2025 • Nasdaq
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround
Jun 3, 2025 • Yahoo Finance
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Jun 2, 2025 • Yahoo Finance
Summit Therapeutics: Market Overreaction Creates Opportunity (NASDAQ:SMMT)
Jun 2, 2025 • Seeking Alpha
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Jun 2, 2025 • Nasdaq
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.
May 30, 2025 • Barron's
Summit Therapeutics stock dips after clinical trial results
May 30, 2025 • Investing.com
Why Summit Therapeutics Plunged Today
May 30, 2025 • Nasdaq
Why Summit Therapeutics Plunged Today
May 30, 2025 • The Motley Fool
Summit shrugs off survival miss with its VEGF bispecific
May 30, 2025 • pharmaphorum
Summit Therapeutics: Critical NSCLC Study Readout Jeopardizes Ivonesimab Approval (SMMT)
May 30, 2025 • Seeking Alpha
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?
May 26, 2025 • Yahoo Finance
Summit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025
May 22, 2025 • Yahoo Finance
What to know about Summit Therapeutics’ looming clinical trial readout
May 15, 2025 • statnews.com
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain
May 9, 2025 • Yahoo Finance
Can Summit Therapeutics Stock Double Your Money?
May 7, 2025 • Nasdaq
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
May 6, 2025 • Yahoo Finance
Why Summit Therapeutics Inc. (SMMT) Soared Last Week
May 4, 2025 • Yahoo Finance
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
May 1, 2025 • BioSpace
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
May 1, 2025 • Business Wire
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Apr 28, 2025 • Benzinga
Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT)
Apr 26, 2025 • Seeking Alpha
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Apr 25, 2025 • Yahoo Finance

Links

www.smmttx.comLinkedInX (Twitter)Crunchbase